crizanlizumab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Sickle Cell Disease

Pending FDA approval to decrease incidence of vascular occlusive disease and risk for stroke associated with sickle cell disease

Next:

Pharmacology

Mechanism of Action

Monoclonal antibody that targets P-selectin mediated multicellular adhesion in sickle cell disease

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.